Thermo Fisher Scientific Opens cGMP Plasmid DNA Manufacturing Facility in Carlsbad, California

- Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, has opened a new cGMP plasmid DNA manufacturing facility in Carlsbad, Calif. enabling it to meet rapidly growing demand for plasmid DNA-based therapies and vital mRNA-based vaccines.

"Demand for commercial plasmid DNA is outpacing supply as the development of transformative gene therapies and vaccines accelerates globally," said Marc N. Casper , chairman, president and chief executive officer, Thermo Fisher Scientific. "Investments in state-of-the-art manufacturing such as this ensure that our customers have reliable access to the high-quality materials and capabilities that have become vital for the production of these new lifesaving medicines and the patients in need."

The 67,000-square-foot facility, located on Thermo Fisher's Carlsbad campus, is part of an investment strategy to ensure customers can reliably meet growing global demand for cell and gene therapies and vaccines. With its fully integrated development, supply chain and manufacturing capabilities, which include viral vector services in Cambridge, Lexington and Plainville, Mass.. Alachua, Fla. and Gosselies and Seneffe, Belgium ; a new cell therapy manufacturing facility in Princeton, N.J.; and a new cryocenter in Weil am Rhein, Germany to support clinical trials, Thermo Fisher customers can quickly progress from discovery to clinical to patient impact.

Plasmid DNA is increasingly used as a therapeutic agent in gene therapies and certain vaccines. Its advantages, including weak immunogenicity, increased safety and ease of manufacture, have dramatically increased demand for materials and manufacturing capacity globally.

The expansion in Carlsbad also benefits the growing life sciences ecosystem in California , and Thermo Fisher will add more than 150 new roles as manufacturing scales. To celebrate the opening of the new facility, Thermo Fisher hosted a ribbon-cutting ceremony today with local government officials including U.S. Representatives Mike Levin and Scott Peters and Carlsbad City Mayor Matt Hall .

"This expansion in Carlsbad is exciting, bringing new jobs and revenue to our district, while also advancing San Diego County's reputation as a hub for innovation," said Rep. Levin, CA-49. "Their work helps tackle many of the world's greatest challenges and builds healthier, more sustainable communities."

Rep. Peters, CA-52 said, "I'm thrilled that this expansion will add jobs, advance medical services manufacturing capabilities in San Diego and California and further bolster our regions' leadership in scientific innovation."

"We're pleased that Thermo Fisher continues to expand its footprint in Carlsbad , and their investment will contribute greatly to our community's economic development and our reputation as a home to innovators who are improving health and medicine globally," said Carlsbad Mayor Matt Hall.

To learn more about Thermo Fisher's new cGMP Plasmid DNA manufacturing facility, please visit www.thermofisher.com/patheon .  Open positions can be found at jobs.thermofisher.com .

About Thermo Fisher Scientific
Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue exceeding $30 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, improving patient diagnostics and therapies or increasing productivity in their laboratories, we are here to support them. Our global team of more than 80,000 colleagues delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services and Patheon. For more information, please visit www.thermofisher.com .

Investments in state-of-the-art manufacturing ensure that Thermo Fisher cell and gene therapy customers have reliable access to the high-quality materials and capabilities that have become vital for the production of new therapies and vaccines.

Media Contact Information:
Ron O'Brien
Thermo Fisher Scientific

Phone: 781-622-1242
E-mail: ron.obrien@thermofisher.com

Investor Contact Information:
Rafael Tejada
Thermo Fisher Scientific

Phone:  781-622-1356
E-mail: rafael.tejada@thermofisher.com

Thermo Fisher Scientific logo (PRNewsfoto/Thermo Fisher Scientific)

Cision View original content to download multimedia: https://www.prnewswire.com/news-releases/thermo-fisher-scientific-opens-cgmp-plasmid-dna-manufacturing-facility-in-carlsbad-california-301334287.html

SOURCE Thermo Fisher Scientific

News Provided by PR Newswire via QuoteMedia

The Conversation (0)

Bausch Health to Announce First-Quarter 2024 Results on May 2

Bausch Health Companies Inc. (NYSE:NHC)(TSX:BHC) will release first-quarter 2024 financial results on Thursday, May 2, 2024. Bausch Health will host a conference call and live webcast at 8:00 a.m. U.S. EST to discuss the results and provide a business update. All materials will be made available on the Investor Relations section of the Bausch Health website prior to the start of the call

Conference Call Details

News Provided by ACCESSWIRE via QuoteMedia

Keep reading...Show less

Court of Appeals for the Federal Circuit Issues Ruling in Norwich Case that Prevents FDA Approval of Norwich's Abbreviated New Drug Application Until 2029

Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), and its gastroenterology business Salix Pharmaceuticals, today announced that the U.S. Court of Appeals for the Federal Circuit in the matter of Salix Pharmaceuticals, LTD. et al v. Norwich Pharmaceuticals, Inc., affirmed the May 17, 2023 decision of the U.S. District Court for the District of Delaware that had denied Norwich Pharmaceuticals, Inc.'s motion for modification of the court's final order preventing the U.S. Food and Drug Administration (FDA) from approving its abbreviated new drug application (ANDA) for XIFAXAN (rifaximin) 550 mg before Oct. 2, 2029. The Court of Appeals also affirmed the August 10, 2022 decision of the District Court that invalidated certain U.S. Patents protecting the composition and use of XIFAXAN® for treating IBS-D. As a result of the Federal Circuit's decision, Norwich's abbreviated new drug application for XIFAXAN (rifaximin) 550 mg remains barred from approval by the U.S. Food and Drug Administration until Oct. 2, 2029

News Provided by ACCESSWIRE via QuoteMedia

Keep reading...Show less

Acne Vulgaris Treatment PrARAZLO Now Available to Patients Through British Columbia PharmaCare Public Drug Plan

Bausch Health, Canada Inc., part of Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), today announced that its topical prescription treatment for acne vulgaris, PrARAZLOTM (tazarotene lotion, 0.045% ww), is now available to patients through BC PharmaCare, the public drug program of British Columbia

ARAZLO is the only tazarotene lotion treatment approved by Health Canada for the topical treatment of acne vulgaris in patients 10 years of age and older.1 The listing by BC PharmaCare means ARAZLO is now available to patients on all public drug plans across Canada.

News Provided by ACCESSWIRE via QuoteMedia

Keep reading...Show less
Cleo Diagnostics

CLEO Appoints CRO to Manage U.S. Ovarian Cancer Clinical Trials

Ovarian cancer diagnostics company, Cleo Diagnostics Limited (ASX:COV) (CLEO, or the Company) is pleased to announce the appointment of international Contract Research Organization (CRO), Lindus Health, as a key partner for its U.S. clinical trials program.

Keep reading...Show less

Medtronic unveils the future of AI in GI: Genius Summit 2024 reveals innovations and collaborations that advance endoscopic care

AI-driven solutions and strategic alliances showcase Medtronic's promise to enhance the efficiency and effectiveness of endoscopy

Medtronic plc (NYSE: MDT), a global leader in healthcare technology, announced the latest advancements in artificial intelligence (AI) for endoscopic care by unveiling ColonPRO™, the latest generation software for the GI Genius™ intelligent endoscopy system, along with a strategic collaboration designed to enhance patient care.

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less

Knight to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference

Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a leading pan-American (ex-US) specialty pharmaceutical company, announced today that Samira Sakhia, President and Chief Executive Officer, is scheduled to present a corporate update at the Bloom Burton & Co. Healthcare Investor Conference on Tuesday, April 16, 2024, at 10:30 a.m. ET at the Metro Toronto Convention Centre in Toronto. A copy of the presentation will be available at www.knighttx.com .

About Knight Therapeutics Inc.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News

×